RÉSUMÉ
OBJECTIVE: The aim of this study was to analyze the temporal trends of HIV epidemiology in Turkey from 2011 to 2016. METHODS: Thirty-four teams from 28 centers at 17 different cities participated in this retrospective study. Participating centers were asked to complete a structured form containing questions about epidemiologic, demographic and clinical characteristics of patients presented with new HIV diagnosis between 2011 and 2016. Demographic data from all centers (complete or partial) were included in the analyses. For the cascade of care analysis, 15 centers that provided full data from 2011 to 2016 were included. Overall and annual distributions of the data were calculated as percentages and the Chi square test was used to determine temporal changes. RESULTS: A total of 2,953 patients between 2011 and 2016 were included. Overall male to female ratio was 5:1 with a significant increase in the number of male cases from 2011 to 2016 (p<0.001). The highest prevalence was among those aged 25-34 years followed by the 35-44 age bracket. The most common reason for HIV testing was illness (35%). While the frequency of sex among men who have sex with men increased from 16% to 30.6% (p<0.001) over the study period, heterosexual intercourse (53%) was found to be the most common transmission route. Overall, 29% of the cases presented with a CD4 count of >500 cells/mm3 while 46.7% presented with a CD4 T cell count of <350 cells/mm3. Among newly diagnosed cases, 79% were retained in care, and all such cases initiated ART with 73% achieving viral suppression after six months of antiretroviral therapy. CONCLUSION: The epidemiologic profile of HIV infected individuals is changing rapidly in Turkey with an increasing trend in the number of newly diagnosed people disclosing themselves as MSM. New diagnoses were mostly at a young age. The late diagnosis was found to be a challenging issue. Despite the unavailability of data for the first 90, Turkey is close to the last two steps of 90-90-90 targets.
Sujet(s)
Infections à VIH/épidémiologie , VIH (Virus de l'Immunodéficience Humaine)/pathogénicité , Hepacivirus/pathogénicité , Virus de l'hépatite B/pathogénicité , Hépatite B/épidémiologie , Hépatite C/épidémiologie , Adolescent , Adulte , Agents antiVIH/usage thérapeutique , Thérapie antirétrovirale hautement active , Numération des lymphocytes CD4 , Lymphocytes T CD4+/effets des médicaments et des substances chimiques , Lymphocytes T CD4+/virologie , Enfant , Enfant d'âge préscolaire , Co-infection , Retard de diagnostic , Femelle , VIH (Virus de l'Immunodéficience Humaine)/effets des médicaments et des substances chimiques , VIH (Virus de l'Immunodéficience Humaine)/physiologie , Infections à VIH/traitement médicamenteux , Infections à VIH/mortalité , Infections à VIH/virologie , Hepacivirus/effets des médicaments et des substances chimiques , Hepacivirus/physiologie , Hépatite B/traitement médicamenteux , Hépatite B/mortalité , Hépatite B/virologie , Virus de l'hépatite B/effets des médicaments et des substances chimiques , Virus de l'hépatite B/physiologie , Hépatite C/traitement médicamenteux , Hépatite C/mortalité , Hépatite C/virologie , Hétérosexualité/statistiques et données numériques , Homosexualité masculine/statistiques et données numériques , Humains , Incidence , Nourrisson , Mâle , Adulte d'âge moyen , Études rétrospectives , Analyse de survie , Turquie/épidémiologie , Charge virale/effets des médicaments et des substances chimiquesRÉSUMÉ
There have been many studies pertaining to the management of herpetic meningoencephalitis (HME), but the majority of them have focussed on virologically unconfirmed cases or included only small sample sizes. We have conducted a multicentre study aimed at providing management strategies for HME. Overall, 501 adult patients with PCR-proven HME were included retrospectively from 35 referral centres in 10 countries; 496 patients were found to be eligible for the analysis. Cerebrospinal fluid (CSF) analysis using a PCR assay yielded herpes simplex virus (HSV)-1 DNA in 351 patients (70.8%), HSV-2 DNA in 83 patients (16.7%) and undefined HSV DNA type in 62 patients (12.5%). A total of 379 patients (76.4%) had at least one of the specified characteristics of encephalitis, and we placed these patients into the encephalitis presentation group. The remaining 117 patients (23.6%) had none of these findings, and these patients were placed in the nonencephalitis presentation group. Abnormalities suggestive of encephalitis were detected in magnetic resonance imaging (MRI) in 83.9% of the patients and in electroencephalography (EEG) in 91.0% of patients in the encephalitis presentation group. In the nonencephalitis presentation group, MRI and EEG data were suggestive of encephalitis in 33.3 and 61.9% of patients, respectively. However, the concomitant use of MRI and EEG indicated encephalitis in 96.3 and 87.5% of the cases with and without encephalitic clinical presentation, respectively. Considering the subtle nature of HME, CSF HSV PCR, EEG and MRI data should be collected for all patients with a central nervous system infection.